Pham, T. C., Nguyen, V. N., Choi, Y., Lee, S. & Yoon, J. Recent strategies to develop innovative photosensitizers for enhanced photodynamic therapy. Chem. Rev. 121, 13454–13619 (2021).
Overchuk, M. et al. Subtherapeutic photodynamic treatment facilitates tumor nanomedicine delivery and overcomes desmoplasia. Nano Lett. 21, 344–352 (2021).
Li, X., Lovell, J. F., Yoon, J. & Chen, X. Clinical development and potential of photothermal and photodynamic therapies for cancer. Nat. Rev. Clin. Oncol. 17, 657–674 (2020).
Yang, W. et al. Size-transformable antigen-presenting cell-mimicking nanovesicles potentiate effective cancer immunotherapy. Sci. Adv. 6, 1631 (2020).
Meng, Z. et al. Light-triggered in situ gelation to enable robust photodynamic-immunotherapy by repeated stimulations. Adv. Mater. 31, 1900927 (2019).
Guo, Y. et al. Copackaging photosensitizer and PD-L1 siRNA in a nucleic acid nanogel for synergistic cancer photoimmunotherapy. Sci. Adv. 8, 2941 (2022).
Huang, Z. et al. Rational vaccinology: harnessing nanoscale chemical design for cancer immunotherapy. ACS Cent. Sci. 8, 692–704 (2022).
Shi, L. et al. An activity-based photosensitizer to reverse hypoxia and oxidative resistance for tumor photodynamic eradication. Adv. Mater. 34, 2206659 (2022).
Li, J. K., Zhang, M. Y., Zeng, L., Huang, L. & Wang, X. Y. NIR-absorbing B, N-heteroarene as photosensitizer for high-performance NIR-to-blue triplet–triplet annihilation upconversion. Angew. Chem. Int. Ed. 62, 202303093 (2023).
Cheng, H. B. et al. Protein-activatable diarylethene monomer as a smart trigger of noninvasive control over reversible generation of singlet oxygen: a facile, switchable, theranostic strategy for photodynamic-immunotherapy. J. Am. Chem. Soc. 143, 2413–2422 (2021).
Yamagishi, K. et al. Tissue-adhesive wirelessly powered optoelectronic device for metronomic photodynamic cancer therapy. Nat. Biomed. Eng. 3, 27–36 (2019).
Gatenby, R. & Brown, J. The evolution and ecology of resistance in cancer therapy. Cold Spring Harb. Perspect. Med. 10, 040971 (2020).
Liu, Y. et al. Tumor selective metabolic reprogramming as a prospective PD-L1 depression strategy to reactivate immunotherapy. Adv. Mater. 34, 2206121 (2022).
Dagogo-Jack, I. & Shaw, A. T. Tumour heterogeneity and resistance to cancer therapies. Nat. Rev. Clin. Oncol. 15, 81–94 (2018).
Kalbasi, A. & Ribas, A. Tumour-intrinsic resistance to immune checkpoint blockade. Nat. Rev. Immunol. 20, 25–39 (2020).
Mali, P., Esvelt, K. M. & Church, G. M. Cas9 as a versatile tool for engineering biology. Nat. Methods 10, 957–963 (2013).
Ran, F. A. et al. Genome engineering using the CRISPR–Cas9 system. Nat. Protoc. 8, 2281–2308 (2013).
Pickar-Oliver, A. & Gersbach, C. A. The next generation of CRISPR–Cas technologies and applications. Nat. Rev. Mol. Cell Biol. 20, 490–507 (2019).
Xu, J. et al. Precise targeting of POLR2A as a therapeutic strategy for human triple negative breast cancer. Nat. Nanotechnol. 14, 388–397 (2019).
Yin, H. et al. Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype. Nat. Biotechnol. 32, 551–553 (2014).
Huang, C., Han, Z., Evangelopoulos, M. & Mirkin, C. A. CRISPR spherical nucleic acids. J. Am. Chem. Soc. 144, 18756–18760 (2022).
Alfarouk, K. O. et al. Resistance to cancer chemotherapy: failure in drug response from ADME to P-gp. Cancer Cell Int. 15, 71 (2015).
Li, L. et al. Multifunctional light-activatable nanocomplex conducting temperate-heat photothermal therapy to avert excessive inflammation and trigger augmented immunotherapy. Biomaterials 290, 121815 (2022).
Wang, N. et al. Multistage sensitive NanoCRISPR enable efficient intracellular disruption of immune checkpoints for robust innate and adaptive immune coactivation. Adv. Funct. Mater. 30, 2004940 (2020).
Yin, H. et al. Non-viral vectors for gene-based therapy. Nat. Rev. Genet. 15, 541–555 (2014).
Sun, Q., Zhou, Z., Qiu, N. & Shen, Y. Rational design of cancer nanomedicine: nanoproperty integration and synchronization. Adv. Mater. 29, 1606628 (2017).
Song, X. et al. Delivery of CRISPR/Cas systems for cancer gene therapy and immunotherapy. Adv. Drug Deliv. Rev. 168, 158–180 (2021).
Liu, J. et al. Programmable delivery of immune adjuvant to tumor-infiltrating dendritic cells for cancer immunotherapy. Nano Lett. 20, 4882–4889 (2020).
Callmann, C. E. et al. Tumor cell lysate-loaded immunostimulatory spherical nucleic acids as therapeutics for triple-negative breast cancer. Proc. Natl Acad. Sci. USA 117, 17543–17550 (2020).
Klinman, D. M. Immunotherapeutic uses of CpG oligodeoxynucleotides. Nat. Rev. Immunol. 4, 249–258 (2004).
Nakano, T. et al. Double-stranded structure of the polyinosinic-polycytidylic acid molecule to elicit TLR3 signaling and adjuvant activity in murine intranasal A(H1N1) pdm09 influenza vaccination. DNA Cell Biol. 39, 1730–1740 (2020).
Mata-Haro, V. et al. The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4. Science 316, 1628–1632 (2007).
Irvine, D. J. & Dane, E. L. Enhancing cancer immunotherapy with nanomedicine. Nat. Rev. Immunol. 20, 321–334 (2020).
Lim, J., Nakamura, B. N., Mohar, I., Kavanagh, T. J. & Luderer, U. Glutamate cysteine ligase modifier subunit (gclm) null mice have increased ovarian oxidative stress and accelerated age-related ovarian failure. Endocrinology 156, 3329–3343 (2015).
Seiwert, N. et al. Heme oxygenase 1 protects human colonocytes against ROS formation, oxidative DNA damage and cytotoxicity induced by heme iron, but not inorganic iron. Cell Death Dis. 11, 787 (2020).
Campbell, N. K., Fitzgerald, H. K. & Dunne, A. Regulation of inflammation by the antioxidant haem oxygenase 1. Nat. Rev. Immunol. 21, 411–425 (2021).
Kishimoto, Y., Kondo, K. & Momiyama, Y. The protective role of heme oxygenase-1 in atherosclerotic diseases. Int. J. Mol. Sci. 20, 3628 (2019).
Yachie, A. Heme oxygenase-1 deficiency and oxidative stress: a review of 9 independent human cases and animal models. Int. J. Mol. Sci. 22, 1514 (2021).
Wan, M. et al. Bio-inspired nitric-oxide-driven nanomotor. Nat. Commun. 10, 966 (2019).
Alloatti, A., Kotsias, F., Magalhaes, J. G. & Amigorena, S. Dendritic cell maturation and cross-presentation: timing matters! Immunol. Rev. 272, 97–108 (2016).
Hu, Y. et al. Cytosolic delivery of membrane-impermeable molecules in dendritic cells using pH-responsive core-shell nanoparticles. Nano Lett. 7, 3056–3064 (2007).
Lugo-Villarino, G., Maldonado-Lopez, R., Possemato, R., Penaranda, C. & Glimcher, L. H. T-bet is required for optimal production of IFN-gamma and antigen-specific T cell activation by dendritic cells. Proc. Natl Acad. Sci. USA 100, 7749–7754 (2003).
Pan, J. et al. Interferon-gamma is an autocrine mediator for dendritic cell maturation. Immunol. Lett. 94, 141–151 (2004).
Luckheeram, R. V., Zhou, R., Verma, A. D. & Xia, B. CD4+ T cells: differentiation and functions. Clin. Dev. Immunol. 2012, 925135 (2012).
Borst, J., Ahrends, T., Babala, N., Melief, C. J. M. & Kastenmuller, W. CD4+ T cell help in cancer immunology and immunotherapy. Nat. Rev. Immunol. 18, 635–647 (2018).
Doroshow, D. B. et al. PD-L1 as a biomarker of response to immune-checkpoint inhibitors. Nat. Rev. Clin. Oncol. 18, 345–362 (2021).
Sanmamed, M. F. & Chen, L. A paradigm shift in cancer immunotherapy: from enhancement to normalization. Cell 175, 313–326 (2018).
Hiller, J. G., Perry, N. J., Poulogiannis, G., Riedel, B. & Sloan, E. K. Perioperative events influence cancer recurrence risk after surgery. Nat. Rev. Clin. Oncol. 15, 205–218 (2018).
Wang, T. et al. A cancer vaccine-mediated postoperative immunotherapy for recurrent and metastatic tumors. Nat. Commun. 9, 1532 (2018).
Hiam-Galvez, K. J., Allen, B. M. & Spitzer, M. H. Systemic immunity in cancer. Nat. Rev. Cancer 21, 345–359 (2021).
Xia, L., Schrump, D. S. & Gildersleeve, J. C. Whole-cell cancer vaccines induce large antibody responses to carbohydrates and glycoproteins. Cell Chem. Biol. 23, 1515–1525 (2016).
Pavlick, A. et al. Combined vaccination with NY-ESO-1 protein, poly-ICLC, and montanide improves humoral and cellular immune responses in patients with high-risk melanoma. Cancer Immunol. Res. 8, 70–80 (2020).
Ma, L. et al. Enhanced CAR-T cell activity against solid tumors by vaccine boosting through the chimeric receptor. Science 365, 162–168 (2019).
Chen, F. et al. Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors. J. Clin. Invest. 129, 2056–2070 (2019).
Zhang, X., Sharma, P. K., Peter Goedegebuure, S. & Gillanders, W. E. Personalized cancer vaccines: targeting the cancer mutanome. Vaccine 35, 1094–1100 (2017).
Sun, C. & Xu, S. Advances in personalized neoantigen vaccines for cancer immunotherapy. Biosci. Trends. 14, 349–353 (2020).
Tureci, O. et al. Targeting the heterogeneity of cancer with individualized neoepitope vaccines. Clin. Cancer Res. 22, 1885–1896 (2016).
Brennick, C. A., George, M. M., Corwin, W. L., Srivastava, P. K. & Ebrahimi-Nik, H. Neoepitopes as cancer immunotherapy targets: key challenges and opportunities. Immunotherapy 9, 361–371 (2017).
Vanmeerbeek, I. et al. Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology. Oncoimmunology 9, 1703449 (2020).
Fucikova, J. et al. Detection of immunogenic cell death and its relevance for cancer therapy. Cell Death Dis. 11, 1013 (2020).
Li, W. et al. Targeting photodynamic and photothermal therapy to the endoplasmic reticulum enhances immunogenic cancer cell death. Nat. Commun. 10, 3349 (2019).
Vasan, N., Baselga, J. & Hyman, D. M. A view on drug resistance in cancer. Nature 575, 299–309 (2019).
Shen, S. et al. A nanotherapeutic strategy to overcome chemotherapeutic resistance of cancer stem-like cells. Nat. Nanotechnol. 16, 104–113 (2021).
Wu, D. et al. Roles of tumor heterogeneity in the development of drug resistance: a call for precision therapy. Semin Cancer Biol. 42, 13–19 (2017).
Chin, A. L. et al. Implantable optical fibers for immunotherapeutic delivery and tumor impedance measurement. Nat. Commun. 12, 5138 (2021).
Samineni, V. K. et al. Fully implantable, battery-free wireless optoelectronic devices for spinal optogenetics. Pain 158, 2108–2116 (2017).
Xu, L. et al. Morphologically virus-like fullerenol nanoparticles act as the dual-functional nanoadjuvant for HIV-1 vaccine. Adv. Mater. 25, 5928–5936 (2013).
Grosjean, C. et al. Isolation and enrichment of mouse splenic T cells for ex vivo and in vivo T cell receptor stimulation assays. STAR Protoc. 2, 100961 (2021).
Wang, N. A HO-1 gene knockout using a NanoCRISPR scaffold suppresses metastasis in mouse models. NCBI SRA https://www.ncbi.nlm.nih.gov/sra/PRJNA1290303 (2025).